Harmony’s Grand Illusion: A Comedy of Profit

by

Behold, a company named Harmony Biosciences, a most curious spectacle indeed! It flourishes, amassing coin with a speed that would delight a merchant prince, yet remains valued as if burdened by a perpetual melancholy. A paradox, you say? Nay, a comedy! For while some whisper of shadows and impropriety – allegations that cling like unwanted courtiers – Harmony persists, plotting further expansion of its dominion over the realm of rare maladies. Let us, with a discerning eye and a touch of amusement, examine this most peculiar performance.

This treatise, the third and final act in our exploration of the Voyager Portfolio‘s potential acquisitions, shall unveil the company’s ambitious designs and the perils that lie in wait. We shall weigh the risks, and determine if the potential rewards are sufficient to justify braving the tempest. For in the world of finance, as in the theatre, one must be prepared for both applause and rotten tomatoes.

Prolonging the Slumber: A Masterful Deception?

Harmony’s sole offering, Wakix, has proven a wondrous success, nearing the status of a blockbuster. Yet, like all earthly delights, its reign is finite, threatened by the inexorable march of time and the expiration of its patent in 2030. To ward off the barbarians at the gate – the generic competitors eager to plunder its profits – Harmony has concocted a scheme: Pitolisant GR, a variant of the original compound, designed to extend its patent protection into the distant future. The studies, they claim, are promising, and the FDA’s response is eagerly anticipated by early 2027. A clever ruse, if it succeeds, though one wonders if such prolonged protection is truly in the best interest of those afflicted.

Furthermore, Pitolisant HD, a second variation, is being tested for its efficacy in treating sleep inertia – a most debilitating condition. Should it prove successful, Harmony shall have expanded its reach into yet another corner of the sleep-deprived world. The results of these trials are expected in 2027, with a potential FDA approval looming in 2028. A bold ambition, to be sure, though one must question whether such relentless pursuit of profit is not, perhaps, a symptom of a deeper malady.

A Pipeline of Promise, or a House of Cards?

Beyond the fortunes of Pitolisant, Harmony boasts a collection of other prospective treatments in the works. BP1.15205, a concoction intended to address a variety of sleep disorders, is currently undergoing preliminary trials. The company anticipates data by mid-year, claiming fewer adverse events and the convenience of once-daily dosing. A tempting prospect, to be certain, though one must remember that many a promising potion has failed to deliver on its promises.

EPX-100, a clemizole hydrochloride compound, is also being investigated for its potential to alleviate seizures in patients with Dravet and Lennox-Gastaut Syndromes. Early trials have shown encouraging results, and topline data is expected in the first half of next year. Should it prove successful, Harmony shall have secured another avenue for profit. Yet, one cannot help but wonder if the relentless pursuit of cures is driven by genuine compassion, or simply by the allure of financial gain.

Does Harmony Deserve a Place in the Voyager Portfolio?

It is ever more difficult to trust in investments where one lacks expertise. Without a grounding in the sciences, it is difficult to evaluate the credibility of a biotech’s claims. I suspect this is the root of the skepticism surrounding Harmony, stemming from the accusations leveled by Scorpion Capital in 2023. Despite years having passed and Harmony’s financial performance remaining strong, doubts linger. Are these accusations mere whispers, or portents of future misfortune?

Loading widget...

However, despite these risks, Harmony’s relatively modest valuation offers a margin of safety – a rare commodity in the volatile world of biotech. Many companies of similar size have yet to bring a single treatment to market, making their success an all-or-nothing gamble. Harmony, by contrast, has a proven track record. For these reasons, and to diversify our holdings, the Voyager Portfolio shall acquire shares of Harmony Biosciences as soon as permissible. I anticipate considerable volatility, but if fortune smiles upon us, this investment may yield substantial rewards.

Read More

2026-01-28 20:15